Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyBlue Cross NC denosumab coverage & prior auth | Op…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - North CarolinaPolicy N/A

    Denosumab (Prolia, Xgeva) and Denosumab Biosimilars notification

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for denosumab products and biosimilars for Blue Cross Blue Shield North Carolina members, covering osteoporosis, cancer-related indications, giant cell tumor of bone, hypercalcemia of malignancy, and related uses.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyDenosumab (Prolia, Xgeva) and Denosumab Biosimilars notification
    Policy CodePolicy N/A
    Change TypeMaterial revisions to biosimilar preferences, site-of-care rules, and coding
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document trials and inadequate response to all listed preferred denosumab biosimilars (or submit MedWatch supporting serious adverse events) to support coverage of non-preferred products.
    SourceLink
    POLICY UPDATE CHANGES

    Added Bildyos (denosumab-nxxp) to preferred Prolia biosimilars and Bilprevda (denosumab-nxxp) to preferred Xgeva biosimilars and updated preferred/non-preferred lists.

    Removed required trial of IV bisphosphonate for certain breast and lung cancer bone metastases indications for Xgeva products and added other indication expansions and restrictions (e.g., castration-resistant prostate cancer, systemic mastocytosis).

    Added Site of Care Medical Necessity Criteria specifying when inpatient or outpatient hospital administration is allowed and alternatives if criteria are not met.

    Updated HCPCS/Coding table: added Q5157, Q5158, Q5159 for specific biosimilars and removed miscellaneous J/C codes for some products.

    >20restricted products listed
    365standard approval duration (days)
    3site-of-care examples
    Q5157-Q5159Q-codes added
    J0897, Q-codesHCPCS/Coding referenced

    Coverage and Medical Necessity Criteria

    Medical necessity — general and indication-specific

    Covered when ALL of the following are met (structure varies by indication — nested AND/OR logic follows):

    Root

    • Age and primary diagnosis

      • Osteoporosis population requirement: For osteoporosis: patient is a male over 50 OR postmenopausal female
      • High fracture risk defined by history of osteoporotic fracture OR multiple risk factors for fracture
      • Prior bisphosphonate criteria: Either prior bisphosphonate therapy with therapeutic failure/inadequate response OR contraindication/hypersensitivity to bisphosphonates
    • Cancer and other indications: For cancer-related and other indications: indication-specific requirements such as current therapy (e.g., aromatase inhibitor for breast cancer; androgen deprivation therapy for nonmetastatic prostate cancer), documented bone metastases when required, prior IV bisphosphonate failure or intolerance where specified, and age limits for giant cell tumor (>=12 years and skeletally mature)
    • Biosimilar preference exceptions: If request is for a non-preferred denosumab product, patient must have tried and had inadequate response to all listed preferred biosimilars OR have intolerance/FDA contraindication/hypersensitivity to those preferred biosimilars OR have a documented serious adverse event to the preferred biosimilars with submission of an FDA MedWatch form
    • Concomitant therapy exclusion: Patient will NOT be using the requested agent in combination with a bisphosphonate, another denosumab product, romosozumab-aqqg, or a parathyroid hormone analog for osteoporosis
    • Quantity and site-of-care: Requested quantity does not exceed maximum units for duration of approval and for inpatient or outpatient hospital administration the Site of Care Criteria apply
    Osteoporosis specific nested: Within osteoporosis criteria, at least one of the age categories and one high-risk definition and one prior bisphosphonate condition must be met

    Site of Care Medical Necessity Criteria

    Administration in inpatient or outpatient hospital setting is allowed only when specified conditions are met; otherwise administration should occur in home or physician office.

    Site of Care - inpatient: For inpatient administration the injection/infusion may be given if the medical necessity criteria are met AND the inpatient admission is NOT for the sole purpose of administering the injection/infusion.
    Site of Care - outpatient hospital: For outpatient hospital administration the injection/infusion may be given if the medical necessity criteria are met AND ONE of the following is true: (a) history of a severe adverse event to the medication (e.g., anaphylaxis, seizure, thromboembolism, myocardial infarction, renal failure); (b) conditions causing increased risk for severe adverse event (e.g., unstable renal function, cardiopulmonary conditions, unstable vascular access); (c) history of mild adverse events not managed with pre-medication; (d) inability to physically or cognitively adhere to treatment schedule; (e) new to therapy (initial injection/infusion or <3 months since initial); (f) re-initiation of therapy as defined by specified gaps; (g) requirement for change in product formulation.
    If criteria not met: If the Site of Care criteria are not met, the injection/infusion will be administered in a home-based infusion or physician office setting with or without supervision by a certified healthcare professional.

    Biosimilar trial-and-failure criteria

    Coverage for non-preferred denosumab biosimilars requires documented trial and failure of specified preferred biosimilars or documented serious adverse events to preferred biosimilars with supporting MedWatch reporting.

    Prolia-lineage non-preferred coverage: Coverage of non-preferred Prolia-lineage denosumab products is allowed when EITHER (1) the patient has tried and had an inadequate response to ALL listed preferred Prolia biosimilars (Bildyos AND Jubbonti AND Stoboclo) with medical record documentation, OR (2) the patient has intolerance/FDA-labeled contraindication/hypersensitivity to those preferred biosimilars, OR (3) the patient has a documented serious adverse event to those preferred biosimilars that required medical intervention and is not anticipated with the requested agent, with the prescriber completing and submitting an FDA MedWatch Adverse Event Reporting Form.
    Xgeva-lineage non-preferred coverage: Coverage of non-preferred Xgeva-lineage denosumab products is allowed when EITHER (1) the patient has tried and had an inadequate response to ALL listed preferred Xgeva biosimilars (Bilprevda AND Osenvelt AND Wyost) with medical record documentation, OR (2) the patient has intolerance/FDA-labeled contraindication/hypersensitivity to those preferred biosimilars, OR (3) the patient has a documented serious adverse event to those preferred biosimilars that required medical intervention and is not anticipated with the requested agent, with the prescriber completing and submitting an FDA MedWatch Adverse Event Reporting Form.
    Xgeva additional requirements:

    Coverage is not allowed when the requested denosumab product is to be used concomitantly with other bone-active agents. Specifically, the patient will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab (for example, Prolia or Xgeva), romosozumab-aqqg, or a parathyroid hormone analog for osteoporosis (e.g., abaloparatide, teriparatide).

    For all restricted denosumab products and indications, the policy prohibits use in combination with other denosumab formulations. Requests for a restricted product will be denied if the patient is receiving or intends to receive another form of denosumab (e.g., Prolia or Xgeva) concurrently; this prohibition is applied uniformly across the restricted product list and indications.

    Requests that do not meet the diagnosis-specific medical necessity criteria, the required prior therapy or step-therapy conditions, or that lack documentation of intolerance/contraindication or required adverse-event reporting will be considered not medically necessary and denied. Additionally, requests exceeding the maximum units allowed for the approved duration or lacking required medical-record documentation (e.g., trials and inadequate response, MedWatch submission when applicable) will be denied.

    Administration in the inpatient setting solely for the purpose of giving the denosumab injection or infusion does not meet Site of Care Medical Necessity Criteria. Inpatient administration is permitted only when the medical necessity criteria are met and the inpatient admission is not for the sole purpose of administering the injection/infusion; otherwise the drug should be administered in a home-based infusion or physician office setting.

    HCPCS, J-codes, ICD-10 and Unit Limits

    Referenced HCPCS CodesHCPCS
    J0897denosumab (Prolia) subcutaneous (SC) injection
    Additional HCPCS/Codes for biosimilarsHCPCS
    Q5136denosumab-bbdz (Jubbonti) subcutaneous (SC) injection
    Q5157denosumab-bmwo (Stoboclo) subcutaneous (SC) injection
    Q5158denosumab-bnht (Conexxence) subcutaneous (SC) injection
    Q5159denosumab-dssb (Ospomyv) / denosumab-kyqq (Bosaya) subcutaneous (SC) injection
    C9399Not otherwise classified HCPCS used for some biosimilars
    J3490Unclassified drugs HCPCS used for some biosimilars
    J3590Unclassified biologics HCPCS used for some biosimilars
    HCPCS / J-codes referencedHCPCS
    J0897denosumab (Xgeva) subcutaneous (SC) injection
    Q5136denosumab-bbdz (Wyost) subcutaneous (SC) injection
    Q5157denosumab-bmwo (Osenvelt) subcutaneous (SC) injection
    Q5158denosumab-bnht (Bomyntra) / Conexxence subcutaneous (SC) injection
    Q5159denosumab-dssb (Xbryk) subcutaneous (SC) injection
    C9399 / J3490 / J3590 / J9999Previously used miscellaneous HCPCS/J-codes for several biosimilars
    Applicable ICD-10 CodesICD-10
    C00.0-C49.9, C4A.0-C4A.9, C50.011-C79.9, C7A.00-C7A.8, C7B.00-C7B.8, C80.0-C86.6, C88.2-C96.Z, D00.00-D09.9, M81.0, M81.8, T50.905, Z51.11, Z51.12, Z79.811, Z87.311ICD-10 codes listed as applicable; cancer diagnosis code must accompany certain codes for oncology use
    Maximum Units — specified per product
    Prolia (denosumab) — maximum units120 units per approval period (HCPCS J0897 / FDA label reference)
    Prolia biosimilars — maximum units120 units per approval period (examples: Jubbonti denosumab-bbdz HCPCS Q5136; Stoboclo denosumab-bmwo also listed with 120 maximum units)
    Xgeva (denosumab) — maximum unitsMaximum units vary by indication; see indication-specific table (HCPCS J0897 reference for Xgeva lineage)
    Xgeva biosimilars — examples of maximumsMultiple myeloma: 1,560 units; Giant cell tumor of bone: 1,800 units; Hypercalcemia of malignancy: 1,800 units (FDA label references for Xgeva and Wyost)
    Maximum Units per indication

    Prior Authorization, Step Therapy, and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for all requests for restricted denosumab products. Authorizations may be issued for up to 365 days (1 year).

    • Effective Date: 2026-01-01
    • Duration of approval: 365 days (1 year)
    Step Therapy

    Biosimilar Step Therapy Required

    Step therapy is required between preferred and non-preferred denosumab biosimilar products. For requests for non-preferred Prolia (denosumab) biosimilars, the patient must have tried and had an inadequate response to ALL specified preferred Prolia biosimilars (examples include Bildyos, Jubbonti, and Stoboclo) or have documented intolerance/contraindication or a documented serious adverse event to those preferred products. For requests for non-preferred Xgeva (denosumab) biosimilars, the patient must have tried and had an inadequate response to ALL specified preferred Xgeva biosimilars (examples include Bilprevda, Osenvelt, and Wyost) or have documented intolerance/contraindication or a documented serious adverse event to those preferred products.

    Background and Clinical Context

    Denosumab products are indicated for multiple bone-related conditions. The policy covers denosumab formulations for the treatment of osteoporosis in adults at high fracture risk (including postmenopausal women and men >50), and for oncologic and related indications including prevention of skeletal-related events in multiple myeloma and bone metastases from solid tumors, treatment of giant cell tumor of bone (age and skeletal maturity criteria apply), and management of hypercalcemia of malignancy. Indication-specific requirements (for example, prior bisphosphonate therapy, prior IV bisphosphonate for some Xgeva-lineage indications, and age thresholds) must be met as described in the medical necessity criteria.

    Key Definitions and Thresholds

    High risk for fracture — definition
    History of osteoporotic fractureMember meets ‘high risk for fracture’ if there is a history of osteoporotic fracture as defined in the policy.
    Multiple risk factors for fractureMember meets ‘high risk for fracture’ if multiple fracture risk factors are present (policy requires one of these criteria to establish high risk).
    One of the required high-risk definitions must be metFor osteoporosis indications, the policy requires documentation of either a prior osteoporotic fracture OR multiple risk factors to establish high fracture risk.
    Glucocorticoid-induced osteoporosis criteria
    Glucocorticoid dose thresholdSystemic glucocorticoid therapy at a daily dosage equal to or greater than 7.5 mg prednisone (or equivalent)
    Duration requirement
    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyDenosumab (Prolia, Xgeva) and Denosumab Biosimilars notification
    Policy CodePolicy N/A
    Change TypeMaterial revisions to biosimilar preferences, site-of-care rules, and coding
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document trials and inadequate response to all listed preferred denosumab biosimilars (or submit MedWatch supporting serious adverse events) to support coverage of non-preferred products.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaHCPCS, J-codes, ICD-10 and Unit LimitsPrior Authorization, Step Therapy, and Documentation RequirementsBackground and Clinical ContextKey Definitions and Thresholds
    For certain Xgeva products and indications, some requests require prior trial and failure of an IV bisphosphonate (e.g., multiple myeloma, select solid tumor bone metastases, systemic mastocytosis) as specified in policy; specifics were added and adjusted across updates.
    Multiple myeloma (Xgeva lineage)Maximum Units = 1,560 (FDA label reference for denosumab/Xgeva and several biosimilars)
    Giant cell tumor of boneMaximum Units = 1,800 (FDA label reference for Xgeva lineage dosing and maximum units)
    Bone metastases / Systemic mastocytosisMaximum Units = 1,560 for bone metastases and systemic mastocytosis for select biosimilars (FDA label entries such as Bomyntra, Xbryk list 1,560)
    Hypercalcemia of malignancyMaximum Units = 1,800 for hypercalcemia of malignancy for Xgeva and some biosimilars per FDA label references
    • Preferred Prolia biosimilars to try first: Bildyos (denosumab-nxxp), Jubbonti (denosumab-bbdz), Stoboclo (denosumab-bmwo)
    • Preferred Xgeva biosimilars to try first: Bilprevda (denosumab-nxxp), Osenvelt (denosumab-bmwo), Wyost (denosumab-bbdz)
    Documentation Required

    Required Documentation

    Medical record documentation is required to demonstrate trials and inadequate response to preferred denosumab biosimilars or IV bisphosphonates, as applicable, or documentation of intolerance/contraindication. Requests must also include documentation that the requested agent will not be used in combination with a bisphosphonate, another form of denosumab, romosozumab-aqqg, or a parathyroid hormone analog for osteoporosis.

    • Medical record documentation of trial and inadequate response to ALL listed preferred biosimilars is required.
    • Documentation of intolerance, FDA labeled contraindication, or hypersensitivity to preferred biosimilars is required when claimed.
    • Documentation that the requested agent will NOT be used in combination with bisphosphonates, another denosumab, romosozumab-aqqg, or parathyroid hormone analogs.
    Documentation Required

    Adverse Event Documentation for Non‑Preferred Biosimilar Exception

    When requesting an exception based on a documented serious adverse event to preferred biosimilars, the prescriber must complete and submit an FDA MedWatch Adverse Event Reporting Form and include this submission in the medical record documentation.

    • Submit completed FDA MedWatch Adverse Event Reporting Form when serious adverse event is cited
    • Document the adverse event in the medical record and show it required medical intervention and is not anticipated with the requested agent
    Denial Risk

    Denial Triggers

    Requests will be denied if medical necessity criteria are not met. Common denial triggers include failure to meet age or diagnosis requirements, lack of documented high fracture risk (for osteoporosis indications), absence of required trial and failure of preferred biosimilars or IV bisphosphonates where specified, use in combination with excluded agents, exceeding maximum allowed units, or missing required documentation.

    • Denial triggers: unmet age/diagnosis criteria, no high fracture risk documentation, no documented trial/failure of preferred products, concurrent use with excluded agents, request exceeds maximum units
    • Missing FDA MedWatch form or inadequate adverse event documentation may result in denial
    Denial Risk

    Site‑of‑Care Denial Risk

    Site of Care criteria apply for injection or infusion administration in inpatient or outpatient hospital settings. Requests for hospital-based administration that do not meet the Site of Care Medical Necessity Criteria will be denied and the administration should be provided in a home-based infusion or physician office setting where criteria are not met.

    • Inpatient: administration allowed only if medical necessity met and admission is not solely for administration
    • Outpatient hospital: one of listed Site of Care criteria must be met (e.g., history of severe adverse event, conditions increasing risk, inability to adhere to regimen, new to therapy, re-initiation, or change in product formulation)
    • If Site of Care criteria are not met, administration must occur in home infusion or physician office setting
    Patient expected to remain on systemic glucocorticoids for at least 6 months
    High fracture risk and prior bisphosphonate conditionPatient must meet high fracture risk (history of osteoporotic fracture or multiple risk factors) AND have prior bisphosphonate therapeutic failure or be unable to receive a bisphosphonate due to contraindication/hypersensitivity per policy
    Maximum Units (definition)
    Definition of Maximum Units (policy reference)Maximum units are those listed by indication in the FDA label reference table and applied in the policy's HCPCS/thresholds table.
    Examples cited in FDA label tableExamples include Multiple myeloma = 1,560; Giant cell tumor of bone = 1,800; Bone metastases/Systemic mastocytosis = 1,560 (entries shown per product/biosimilar in FDA reference notes).
    Application to biosimilars and productsPolicy lists maximum units per indication for both Prolia/Xgeva and multiple denosumab biosimilars using the FDA label reference table values.